Skip to main content
Top
Published in: BMC Pregnancy and Childbirth 1/2019

Open Access 01-12-2019 | Pre-Eclampsia | Research article

A cross sectional study to assess the sFlt-1:PlGF ratio in pregnant women with and without preeclampsia

Authors: Vivek Pant, Binod Kumar Yadav, Jyoti Sharma

Published in: BMC Pregnancy and Childbirth | Issue 1/2019

Login to get access

Abstract

Background

Preeclampsia is a multisystem disorder characterized by vascular endothelial malfunction occurring after 20 weeks of gestation. Placental soluble fms-like tyrosine kinase-1 (sFlt-1) is an antiangiogenic factor and placental growth factor (PlGF) is a potent angiogenic factor. The imbalance between these factors during placenta and fetal development has been shown to play a role in endothelial damage in preeclampsia.
Preeclampsia is the leading cause of maternal mortality in Nepal. This study was designed to compare the sFlt1:PLGF ratio in pregnant women with and without preeclampsia attending Tribhuvan University Teaching Hospital (TUTH).

Method

An observational cross-sectional study was performed in the Gynecology and Obstetrics Department of TUTH involving forty-four subjects with preeclampsia and forty-four age- and gestational-week-matched normal pregnant subjects as controls. Blood pressure, urinary protein levels, serum sFlt-1 levels, serum PlGF levels and the sFlt-1:PlGF ratio was compared in both the cases and control. The concentrations of sFlt-1 and PlGF were measured with commercially available ELISA kits. SPSS ver. 20.0 was used to analyze the data.

Results

There was no significant difference in age or gestational age in either study group. The ratio of the sFlt-1 and PlGF concentrations was significantly higher in women with preeclampsia (31.6 ± 9.6) than in the controls (3.2 ± 1.3). Likewise, diastolic blood pressure was significantly associated (p-value 0.000), whereas the severity of proteinuria was not associated (p-value 0.773) with the sFlt-1:PlGF ratio in women with preeclampsia. The significantly higher ratio (35.51 ± 8.1 versus 25.4 ± 8.7) was found in women with preeclampsia who developed complications than the group of women with preeclampsia who did not develop complication.

Conclusion

The sFlt-1:PlGF ratio is significantly higher in Nepalese women with preeclampsia than in normal controls and this finding can be applied for further planned clinical trials.
Literature
1.
go back to reference American College of Obstetricians and Gynecologists. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ task force on hypertension in pregnancy. Obstetrics and gynecology. 2013 Nov;122(5):1122.CrossRef American College of Obstetricians and Gynecologists. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ task force on hypertension in pregnancy. Obstetrics and gynecology. 2013 Nov;122(5):1122.CrossRef
2.
go back to reference Matthys LA, Coppage KH, Lambers DS, Barton JR, Sibai BM. Delayed postpartum preeclampsia: an experience of 151 cases. Am J Obstet Gynecol. 2004 May 1;190(5):1464–6.CrossRef Matthys LA, Coppage KH, Lambers DS, Barton JR, Sibai BM. Delayed postpartum preeclampsia: an experience of 151 cases. Am J Obstet Gynecol. 2004 May 1;190(5):1464–6.CrossRef
3.
go back to reference Saadat M, Nejad SM, Habibi G, Sheikhvatan M. Maternal and neonatal outcomes in women with preeclampsia. Taiwanese Journal of Obstetrics and Gynecology. 2007 Sep 1;46(3):255–9.CrossRef Saadat M, Nejad SM, Habibi G, Sheikhvatan M. Maternal and neonatal outcomes in women with preeclampsia. Taiwanese Journal of Obstetrics and Gynecology. 2007 Sep 1;46(3):255–9.CrossRef
4.
go back to reference LaMarca B. Endothelial dysfunction; an important mediator in the pathophysiology of hypertension during preeclampsia. Minerva Ginecol. 2012 Aug;64(4):309.PubMedPubMedCentral LaMarca B. Endothelial dysfunction; an important mediator in the pathophysiology of hypertension during preeclampsia. Minerva Ginecol. 2012 Aug;64(4):309.PubMedPubMedCentral
5.
go back to reference Cunningham FG, Leveno KJ, Bloom SL, Hauth JC, Rouse DJ, Spong CY. Pregnancy hypertension. Williams’s obstetrics. 2010;23:706. Cunningham FG, Leveno KJ, Bloom SL, Hauth JC, Rouse DJ, Spong CY. Pregnancy hypertension. Williams’s obstetrics. 2010;23:706.
6.
go back to reference Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003 Jun;9(6):669.CrossRef Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003 Jun;9(6):669.CrossRef
7.
go back to reference Roskoski R Jr. VEGF receptor protein–tyrosine kinases: structure and regulation. Biochem Biophys Res Commun. 2008 Oct 24;375(3):287–91.CrossRef Roskoski R Jr. VEGF receptor protein–tyrosine kinases: structure and regulation. Biochem Biophys Res Commun. 2008 Oct 24;375(3):287–91.CrossRef
8.
go back to reference Keyt BA, Nguyen HV, Berleau LT, Duarte CM, Park J, Chen H, Ferrara N. Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors generation of receptor-selective VEGF variants by site-directed mutagenesis. J Biol Chem. 1996 Mar 8;271(10):5638–46.CrossRef Keyt BA, Nguyen HV, Berleau LT, Duarte CM, Park J, Chen H, Ferrara N. Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors generation of receptor-selective VEGF variants by site-directed mutagenesis. J Biol Chem. 1996 Mar 8;271(10):5638–46.CrossRef
9.
go back to reference Robinson CJ, Stringer SE. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci. 2001 Mar 1;114(5):853–65.PubMed Robinson CJ, Stringer SE. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci. 2001 Mar 1;114(5):853–65.PubMed
10.
go back to reference Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem. 1994 Oct 28;269(43):26988–95.PubMed Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem. 1994 Oct 28;269(43):26988–95.PubMed
11.
go back to reference Heldin CH. Dimerization of cell surface receptors in signal transduction. Cell. 1995 Jan 27;80(2):213–23.CrossRef Heldin CH. Dimerization of cell surface receptors in signal transduction. Cell. 1995 Jan 27;80(2):213–23.CrossRef
12.
go back to reference Wathén KA, Tuutti E, Stenman UH, Alfthan H, Halmesmäki E, Finne P, Ylikorkala O, Vuorela P. Maternal serum-soluble vascular endothelial growth factor receptor-1 in early pregnancy ending in preeclampsia or intrauterine growth retardation. J. Clin. Endocrinol. Metabol. 2006 Jan 1;91(1):180–4.CrossRef Wathén KA, Tuutti E, Stenman UH, Alfthan H, Halmesmäki E, Finne P, Ylikorkala O, Vuorela P. Maternal serum-soluble vascular endothelial growth factor receptor-1 in early pregnancy ending in preeclampsia or intrauterine growth retardation. J. Clin. Endocrinol. Metabol. 2006 Jan 1;91(1):180–4.CrossRef
13.
go back to reference Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003 Mar 1;111(5):649–58.CrossRef Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003 Mar 1;111(5):649–58.CrossRef
14.
go back to reference Ghimire S. Eclampsia: Feto-maternal outcomes in a tertiary Care Centre in Eastern Nepal. J Nepal Med Assoc. 2016 Jan;1:54(201). Ghimire S. Eclampsia: Feto-maternal outcomes in a tertiary Care Centre in Eastern Nepal. J Nepal Med Assoc. 2016 Jan;1:54(201).
15.
go back to reference Thangaratinam S, Langenveld J, Mol BW, Khan KS. Prediction and primary prevention of pre-eclampsia. Best Pract. Res Clin Obstet & Gynaecol. 2011 Aug 1;25(4):419–33.CrossRef Thangaratinam S, Langenveld J, Mol BW, Khan KS. Prediction and primary prevention of pre-eclampsia. Best Pract. Res Clin Obstet & Gynaecol. 2011 Aug 1;25(4):419–33.CrossRef
16.
go back to reference Tsatsaris V, Goffin F, Munaut C, Brichant JF, Pignon MR, Noel A, Schaaps JP, Cabrol D, Frankenne F, Foidart JM. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. J. Clin. Endocrinol. Metabol. 2003 Nov 1;88(11):5555–63.CrossRef Tsatsaris V, Goffin F, Munaut C, Brichant JF, Pignon MR, Noel A, Schaaps JP, Cabrol D, Frankenne F, Foidart JM. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. J. Clin. Endocrinol. Metabol. 2003 Nov 1;88(11):5555–63.CrossRef
17.
go back to reference De Vivo A, Baviera G, Giordano D, Todarello G, Corrado F, D'anna R. Endoglin, PlGF and sFlt-1 as markers for predicting pre-eclampsia. Acta Obstet Gynecol Scand. 2008 Aug;87(8):837–42.CrossRef De Vivo A, Baviera G, Giordano D, Todarello G, Corrado F, D'anna R. Endoglin, PlGF and sFlt-1 as markers for predicting pre-eclampsia. Acta Obstet Gynecol Scand. 2008 Aug;87(8):837–42.CrossRef
18.
go back to reference Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, Karumanchi SA. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 2006 Sep 7;355(10):992–1005.CrossRef Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, Karumanchi SA. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 2006 Sep 7;355(10):992–1005.CrossRef
19.
go back to reference Kim SY, Ryu HM, Yang JH, Kim MY, Han JY, Kim JO, Chung JH, Park SY, Lee MH, Kim DJ. Increased sFlt-1 to PlGF ratio in women who subsequently develop preeclampsia. J Korean Med Sci. 2007 Oct 1;22(5):873–7.CrossRef Kim SY, Ryu HM, Yang JH, Kim MY, Han JY, Kim JO, Chung JH, Park SY, Lee MH, Kim DJ. Increased sFlt-1 to PlGF ratio in women who subsequently develop preeclampsia. J Korean Med Sci. 2007 Oct 1;22(5):873–7.CrossRef
20.
go back to reference Gurnadi JI, Mose J, Handono B, Satari MH, Anwar AD, Fauziah PN, Pramatirta AY, Rihibiha DD. Difference of concentration of placental soluble fms-like tyrosine kinase-1 (sFlt-1), placental growth factor (PlGF), and sFlt-1/PlGF ratio in severe preeclampsia and normal pregnancy. BMC research notes. 2015 Dec;8(1):534.CrossRef Gurnadi JI, Mose J, Handono B, Satari MH, Anwar AD, Fauziah PN, Pramatirta AY, Rihibiha DD. Difference of concentration of placental soluble fms-like tyrosine kinase-1 (sFlt-1), placental growth factor (PlGF), and sFlt-1/PlGF ratio in severe preeclampsia and normal pregnancy. BMC research notes. 2015 Dec;8(1):534.CrossRef
21.
go back to reference Lam C, Lim K-H, Karumanchi SA. Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension. 2005;46(5):1077–85.CrossRef Lam C, Lim K-H, Karumanchi SA. Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension. 2005;46(5):1077–85.CrossRef
22.
go back to reference Stepan H, Geide A, Faber R. Soluble fms-like tyrosine kinase 1. N Engl J Med. 2004 Nov 18;351(21):2241–2.CrossRef Stepan H, Geide A, Faber R. Soluble fms-like tyrosine kinase 1. N Engl J Med. 2004 Nov 18;351(21):2241–2.CrossRef
23.
go back to reference Chaiworapongsa T, Romero R, Espinoza J, Bujold E, Kim YM, Gonçalves LF, Gomez R, Edwin S. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia: young investigator award. Am. J Obstet. Gynecol. 2004 Jun 1;190(6):1541–7.CrossRef Chaiworapongsa T, Romero R, Espinoza J, Bujold E, Kim YM, Gonçalves LF, Gomez R, Edwin S. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia: young investigator award. Am. J Obstet. Gynecol. 2004 Jun 1;190(6):1541–7.CrossRef
24.
go back to reference Buhimschi CS, Norwitz ER, Funai E, Richman S, Guller S, Lockwood CJ, Buhimschi IA. Urinary angiogenic factors cluster hypertensive disorders and identify women with severe preeclampsia. Am. J. Obstet. Gynecol. 2005 Mar 1;192(3):734–41.CrossRef Buhimschi CS, Norwitz ER, Funai E, Richman S, Guller S, Lockwood CJ, Buhimschi IA. Urinary angiogenic factors cluster hypertensive disorders and identify women with severe preeclampsia. Am. J. Obstet. Gynecol. 2005 Mar 1;192(3):734–41.CrossRef
25.
go back to reference Barton JR, O’Brien JM, Bergauer NK, Jacques DL, Sibai BM. Mild gestational hypertension remote from term: progression and outcome. Am. J. Obstet. Gynecol. 2001 Apr 1;184(5):979–83.CrossRef Barton JR, O’Brien JM, Bergauer NK, Jacques DL, Sibai BM. Mild gestational hypertension remote from term: progression and outcome. Am. J. Obstet. Gynecol. 2001 Apr 1;184(5):979–83.CrossRef
26.
go back to reference Dong X, Gou W, Li C, Wu M, Han Z, Li X, Chen Q. Proteinuria in preeclampsia: not essential to diagnosis but related to disease severity and fetal outcomes. Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health. 2017 Apr 1;8:60–4.CrossRef Dong X, Gou W, Li C, Wu M, Han Z, Li X, Chen Q. Proteinuria in preeclampsia: not essential to diagnosis but related to disease severity and fetal outcomes. Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health. 2017 Apr 1;8:60–4.CrossRef
27.
go back to reference Reiss RE, O'Shaughnessy RW, Quilligan TJ, Zuspan FP. Retrospective comparison of blood pressure course during preeclamptic and matched control pregnancies. Am. J. Obstet. Gynecol. 1987 Apr 1;156(4):894–8.CrossRef Reiss RE, O'Shaughnessy RW, Quilligan TJ, Zuspan FP. Retrospective comparison of blood pressure course during preeclamptic and matched control pregnancies. Am. J. Obstet. Gynecol. 1987 Apr 1;156(4):894–8.CrossRef
28.
go back to reference Kearns AD, Caglia JM, Hoope-Bender P, Langer A. Antenatal and postnatal care: a review of innovative models for improving availability, accessibility, acceptability and quality of services in low-resource settings. BJOG Int J Obstet Gynaecol. 2016 Mar 1;123(4):540–8.CrossRef Kearns AD, Caglia JM, Hoope-Bender P, Langer A. Antenatal and postnatal care: a review of innovative models for improving availability, accessibility, acceptability and quality of services in low-resource settings. BJOG Int J Obstet Gynaecol. 2016 Mar 1;123(4):540–8.CrossRef
29.
go back to reference Wikström AK, Larsson A, Eriksson UJ, Nash P, Nordén-Lindeberg S, Olovsson M. Placental growth factor and soluble FMS-like tyrosine kinase-1 in early-onset and late-onset preeclampsia. Obstet Gynecol. 2007 Jun 1;109(6):1368–74.CrossRef Wikström AK, Larsson A, Eriksson UJ, Nash P, Nordén-Lindeberg S, Olovsson M. Placental growth factor and soluble FMS-like tyrosine kinase-1 in early-onset and late-onset preeclampsia. Obstet Gynecol. 2007 Jun 1;109(6):1368–74.CrossRef
30.
go back to reference Lisonkova S, Joseph KS. Incidence of preeclampsia: risk factors and outcomes associated with early-versus late-onset disease. Am J Obstet Gynecol. 2013 Dec 1;209(6):544–e1.CrossRef Lisonkova S, Joseph KS. Incidence of preeclampsia: risk factors and outcomes associated with early-versus late-onset disease. Am J Obstet Gynecol. 2013 Dec 1;209(6):544–e1.CrossRef
31.
go back to reference Ferrazzi E, Stampalija T, Aupont JE. The evidence for late-onset pre-eclampsia as a maternogenic disease of pregnancy. Fetal and Maternal Medicine Review. 2013 Feb;24(1):18–31.CrossRef Ferrazzi E, Stampalija T, Aupont JE. The evidence for late-onset pre-eclampsia as a maternogenic disease of pregnancy. Fetal and Maternal Medicine Review. 2013 Feb;24(1):18–31.CrossRef
32.
go back to reference Zeisler H, Llurba E, Chantraine F, Vatish M, Staff AC, Sennström M, Olovsson M, Brennecke SP, Stepan H, Allegranza D, Dilba P. Predictive value of the sFlt-1: PlGF ratio in women with suspected preeclampsia. N Engl J Med. 2016 Jan 7;374(1):13–22.CrossRef Zeisler H, Llurba E, Chantraine F, Vatish M, Staff AC, Sennström M, Olovsson M, Brennecke SP, Stepan H, Allegranza D, Dilba P. Predictive value of the sFlt-1: PlGF ratio in women with suspected preeclampsia. N Engl J Med. 2016 Jan 7;374(1):13–22.CrossRef
Metadata
Title
A cross sectional study to assess the sFlt-1:PlGF ratio in pregnant women with and without preeclampsia
Authors
Vivek Pant
Binod Kumar Yadav
Jyoti Sharma
Publication date
01-12-2019
Publisher
BioMed Central
Keyword
Pre-Eclampsia
Published in
BMC Pregnancy and Childbirth / Issue 1/2019
Electronic ISSN: 1471-2393
DOI
https://doi.org/10.1186/s12884-019-2399-z

Other articles of this Issue 1/2019

BMC Pregnancy and Childbirth 1/2019 Go to the issue